Abstract |
The kinetics of zimeldine (Z) and its demethylated metabolite, norzimelidine (NZ), were determined after administration of a single 200 mg oral dose of Z to 6 healthy volunteers (Group I), and to patients with mild (Group II) and severe renal failure (Group III). Z and NZ concentrations were assayed by HPLC in serial plasma and urine samples over 6 days following the dose. In Group I Z was rapidly absorbed and metabolized into NZ, and then the plasma concentrations declined with apparent elimination half-lives of 8.4 h and 24.9 h for Z and NZ respectively, whilst the renal clearance of both compounds was low, Z 15.7 ml/min and NZ 33.0 ml/min. The plasma level of Z differed little between Groups I and III, but the area under the curve was significantly higher in Group III than in Group I subjects (AUC0-144 = 17.3 and 6.8 mumol X l-1 X h, respectively). Severe renal failure did not affect the peak plasma concentration of NZ but it did significantly increase peak time, apparent elimination half-life, and the area under the plasma concentration curve. A significant inverse relationship was found between renal clearance of NZ and plasma creatinine. Since NZ is as pharmacologically potent as Z, the results suggest that the dose of Z should be reduced in patients with severe renal insufficiency.
|
Authors | N Ferry, G Cuisinaud, P Cochat, N Pozet, P Y Zech, J Sassard |
Journal | European journal of clinical pharmacology
(Eur J Clin Pharmacol)
Vol. 28
Issue 4
Pg. 453-6
( 1985)
ISSN: 0031-6970 [Print] Germany |
PMID | 3161742
(Publication Type: Journal Article)
|
Chemical References |
- Antidepressive Agents
- Zimeldine
- norzimelidine
|
Topics |
- Adult
- Antidepressive Agents
(metabolism)
- Female
- Humans
- Kidney
(metabolism)
- Kidney Diseases
(metabolism)
- Kinetics
- Male
- Middle Aged
- Zimeldine
(analogs & derivatives, metabolism)
|